Summary
In May 2026, the FDA approved AstraZeneca's BAXFENDY (baxdrostat), the world's first aldosterone synthase inhibitor (ASI), marking the arrival of an entirely new pharmacological class for a condition that affects 1.4 billion people globally.
The approval addresses a stubborn clinical gap. Despite existing options like ACE inhibitors, ARBs, and calcium channel blockers, nearly 23 million Americans with hypertension remain uncontrolled even on multiple medications.
BAXFENDY's FDA approval is backed by the landmark BaxHTN Phase III trial, which demonstrated a placebo-adjusted reduction of nearly 10 mmHg in systolic blood pressure.
Baxfendy opens a la...
